Skip to main content
International Journal of Clinical and Experimental Medicine logoLink to International Journal of Clinical and Experimental Medicine
. 2015 Jan 9;8(2):2226–2232.

Effects of Shenqi Neijin powder on activation and apoptosis of hepatic stellate cells in rats with hepatic fibrosis

Hongdong Xie 1, Wei Hou 1, Yide Yang 1, Ying Yu 1, Fengling Wang 1, Juanjuan Mao 1
PMCID: PMC4402802  PMID: 25932155

Abstract

Traditional herbal medicine is usually administrated according to experiences and practices. We aimed to investigate the anti-fibrotic effects of Shenqi Neijin powder (SQNJP) in hepatic fibrosis rats induced by carbon tetrachloride (CCl4). A total of 32 rats were divided into control group, model group, and SQNJP group. The hydroxyproline content was assayed. Histological features of liver tissues were determined with different staining methods. Western blotting analysis and immuno-fluorescence staining were performed to determine the expression of alpha-smooth muscle actin (α-SMA) and the activation of hepatic stellate cells (HSCs). Serial sections were stained with α-SMA immuno-fluorescence staining and the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling method (TUNEL) in turn to detect the apoptosis of HSCs. Fatty degeneration, deposition of collagen, and interval of fibers were noticed in rats induced by CCl4. After administration of SQNJP, remarkable decrease of fatty degeneration, deposition of collagen, and hydroxyproline content were noticed. Compared with the model group, significant decrease of α-SMA protein was noticed after administration of SQNJP, and remarkable apoptosis of HSCs was noticed after treating with SQNJP. SQNJP showed anti-fibrotic effects through inhibiting HSCs activation and inducing apoptosis of HSCs.

Keywords: Apoptosis, hepatic fibrosis, hepatic stellate cells, SQNJP

Introduction

Hepatic fibrosis refers to the accumulation of extracellular matrix (ECM) or scar in response to acute or chronic liver injuries [1]. Hepatic stellate cells (HSCs) have been considered as the main source of mesenchymal cells involved in hepatic fibrosis. To our knowledge, liver fibrosis is closely related to activation of HSCs, a process characterized by increased cellular proliferation, transformation of fibroblasts into myofibroblasts, increased expression of alpha-smooth muscle actin (α-SMA) and excessive accumulation of ECM [2,3]. Currently, termination of the proliferation of activated HSCs by cell apoptosis has been considered as a promising strategy for hepatic fibrosis treatment. For example, Wang et al reported that ursolic acid could ameliorate the hepatic fibrosis in rat model through specific induction of HSCs apoptosis [4]. Meanwhile, apoptosis of hepatic stellate cells played an important role in the spontaneous recovery of biliary fibrosis in rats subjected to bile duct ligation [5]. Unfortunately, no effective and targeted anti-fibrotic drugs have been approved by FDA, demonstrating an extreme need for the investigation of hepatic fibrosis treatment.

Traditional herbal medicine with a history of more than thousands of years is based on experiences and practices. To date, several herbal medicines have been used to treat liver fibrosis, and have been approved to be efficacious in clinical practices [6,7]. Shenqi Neijin powder (SQNJP), a traditional Chinese medicine formula consisted of Panax quinquefolius, Radix notoginseng, and endothelium corneum gigeriae galli, has been widely used for the treatment of various liver conditions in China mainland [8]. Despite its popularity for the treatment of hepatic diseases, data related to its quality standardization or the mechanism are still lacking. In our previous study, SQNJP plus lamivudine has been used for the hepatic cirrhosis of patients with chronic hepatitis B, and the results were satisfactory [9]. On this basis, we strongly believe that SQNJP may play an important role in the control of hepatic fibrosis. Thus, we investigate the potential efficacy of SQNJP on the cellular activation and/or apoptosis in experimental hepatic fibrosis rats in this study.

Materials and methods

Animals

Male Sprague Dawley rats weighing 160±10 g were purchased from Shanghai Laboratory Animal Center. The animals were housed under controlled temperatures and a 12 h/12 h light/dark cycle with food and water. All the experiments were performed adhered to the Principles of Laboratory Animal Care (NIH Publication No. 86-23, revised 1985) and the regulation of the Committee on the Use and Care of Animals of Fudan University (Shanghai, China). This study was approved by the Ethics Committee of the Taizhou Municipal Hospital (Taizhou, China).

Preparation of SQNJP

SQNJP was made from 30 g Panax quinquefolius, 30 g Radix notoginseng, and 60 g endothelium corneum gigeriae galli. The mixture was ground into powder, and was kept at room temperature until usage.

Induction of hepatic fibrosis in rats

The induction of rats with hepatic fibrosis was carried out as previously described [10]. In brief, single administration of carbon tetrachloride (CCl4, Sinopharm Chemical Reagent Co., Ltd. Shanghai, China) was given via subcutaneous injection at a dose of 5 ml/kg body weight for the first time. For the following induction, 40% CCl4 in olive oil was administrated via subcutaneous injection at a dose of 3 ml/kg body weight. The administration was performed twice a week for 6 weeks.

Experimental design

The animals were divided into: a) control group (n=8), which were subjected to intragastric administration of physiological saline daily for two weeks; b) model group (n=12), which were subjected to intragastric administration of physiological saline daily after the induction of hepatic fibrosis using CCl4 for two weeks; and c) SQNJP group (n=12), which were subjected to intragastric administration of SQNJP powder at a dose of 0.8 g/kg body weight daily after the induction of hepatic fibrosis for two weeks.

Histological determination

Neutral formalin-fixed liver tissues were embedded using paraffin. These samples were then cut into a 5 μm in depth. Subsequently, the samples were stained using hematoxylin and eosin and sirius red, respectively.

Measurement of hepatic hydroxyproline content

The level of hydroxyproline was detected using Jamall’s method [11]. Briefly, 100 mg liver tissues were homogenized at 4°C. After the affiliation of 12 mol/L HCl, the mixture was incubated at 105°C for 18 hours. After hydrolysis, samples were neutralized with 10 mol/L NaOH, oxidized with chloramine-T, and incubated in Ehrlich’s perchloric acid solution at 50°C for 90 minutes. A wavelength of 558 nm was chosen for the absorbance. Hepatic collagen content was analyzed by Sirius red staining of paraffin-embedded sections.

Western blotting analysis of α-SMA protein

Western blotting analysis was performed as routinely described [12]. In brief, the tissues sections were homogenized in RIPA lysis buffer containing protease and phosphatase inhibitors. Proteins were separated by electrophoresis on a 10% SDS-PAGE gel and transferred to a Hybond-P PVDF membrane. Subsequently, the membrane was blocked in 5% nonfat milk and incubated with an α-SMA primary antibody (1:1000 dilution, Sigma-Aldrich Inco., St. Louis, MO, USA) overnight at 4°C, followed by incubation with the peroxidase-conjugated secondary antibody (1:1000 dilution, Sigma-Aldrich Inco., St. Louis, MO, USA) for 1 h at room temperature. After washing with PBS, the bound primary antibody was visualized with the ECL western blotting substrate kit. Then the images were captured using a Bio-Rad Imager system, and were analyzed with Quantity One software (Bio-Rad Inco., Hercules, CA, USA). The same membrane was probed for GAPDH for loading control. The relative density of α-SMA to GAPDH represented the expression of α-SMA. All the experiments were carried out in triplicates.

Immuno-fluorescence staining of α-SMA

Tissue sections were incubated with a monoclonal goat anti-mice α-SMA primary antibody (1:1000 dilution, Sigma-Aldrich Inco., St. Louis, MO, USA) overnight at 4°C, followed by incubation with the rose Bengal-conjugated goat anti-mice IgG (1:1000 dilution, Sigma-Aldrich Inco., St. Louis, MO, USA) for 2 h at room temperature. Then the sections were observed using a TCS-SP2 confocal laser microscopy (Heidelberg, Germany).

Immuno-fluorescence staining and TUNEL staining of α-SMA and apoptosis cells

Three rats were sacrificed at 72 h after the last intragastric administration in each group. The optimal cutting temperature (OCT) compound embedded liver tissues were fixed using frozen acetone. Subsequently, the sections were incubated with 5% goat serum to reduce nonspecific background staining, followed by α-SMA primary antibody (1:1000 dilution, Sigma-Aldrich Inco., St. Louis, MO, USA) for overnight incubation at 4°C. After that, the sections were incubated with rose Bengal linked goat anti mice IgG (1:1000 dilution, Sigma-Aldrich Inco., St. Louis, MO, USA) for 2 h at room temperature. TUNEL staining was performed using a commercial kit (Dead End ® Fluorometric TUNEL system,) purchased from KeyGen Biotech Co., Ltd. Finally, specimen were observed and photographed under a FV1000 confocal laser microscopy (Olympus Inco., Tokyo, Japan).

Statistical analysis

All the data were presented as mean ± standard deviation. SPSS 12.0 software was used for the data analysis. ANOVA post hoc analysis (q test) was carried out for the inter-group comparison. P < 0.05 demonstrated statistical difference.

Results

Histological measurements

The anatomical structure of hepatic lobule and hepatocytes was normal and slight collagen deposition was identified in the peripheral blood vessels of portal area in control group. Swelling of hepatocytes was noticed in model group. Meanwhile, significant vacuolar degeneration was observed in hepatic fatty tissues. Ballooning degeneration and dispersed necrosis were noticed in majority of hepatocytes. Inflammatory cell infiltration was noticed in the portal area and interval of fibers. Significant fibroplasia and deposition were observed in the collagen fibers located in the portal area and the hepatocytes with severe fatty degeneration, partial of which transformed to interval of fibers to separate the hepatic lobule. For the SQNJP group, significant amelioration was noticed in the fatty degeneration, inflammation, necrosis, and infiltration of inflammatory cells. Meanwhile, deposition of collagen fiber showed remarkable decrease (Figure 1).

Figure 1.

Figure 1

HE staining (A-C: A: normal group; B: model group; C: SQNJP group) and Sirius red staining (D-F: D: normal group; E: model group; F: SQNJP group) resultsof hepatic tissues. The images were observed with a magnification of 200×.

Hydroxyproline content decreased after administration of SQNJP

As indicated in Table 1, significant increase was noted in the concentration of hydroxyproline in hepatic tissues after hepatic fibrosis compared with normal group (P < 0.01, Table 1). However, the level of hydroxyproline showed remarkable decrease in SQNJP group compared with the model group (P < 0.01). No statistical difference was noted in the concentration of hydroxyproline in hepatic tissues in the SQNJP group compared with the control group (P > 0.05).

Table 1.

Effects of SQNJP on Hydroxyproline content

Group N Concentration (μg/g)
Control group 8 203.39±30.05
Model group 10 610.64±68.40**
SQNJP group 11 314.85±52.07##
**

P < 0.01, compared with control group;

##

P < 0.01, compared with model group.

Expression of α-SMA protein attenuated after administration of SQNJP

Results of immunohistochemical staining showed slight expression of α-SMA protein in the vessel walls in the animals of control group (Figure 2). Nevertheless, enhanced expression of α-SMA protein was noticed in model group. The expression was mainly distributed in the interval of liver fibers, especially the hepatic tissues with fatty degeneration. Compared with the model group, significant decrease was noticed in the staining intensity of α-SMA protein in the SQNJP group, and at the same time, the expression of α-SMA protein in the SQNJP group showed a strip-like pattern (Figures 2 and 3).

Figure 2.

Figure 2

Immunohistochemical results of α-SMA protein in liver tissues in control group (A), model group (B), and SQNJP group (C) under a magnification of 200×.

Figure 3.

Figure 3

Expression of α-SMA and GAPDH as indicated by Western blotting analysis (A). Semi-quantitative analysis of α-SMA using GAPDH as an internal standard (B). **, P < 0.01, compared with control group; ##, P < 0.01, compared with model group.

Apoptosis of HSCs after administration of SQNJP powder

To investigate whether SQNJP induces apoptosis in hepatic fibrosis rats, TUNEL assay was performed. Few α- SMA positive staining cells were noticed in the control group. No positive staining cell of TUNEL was noticed in control group. For the model group, few TUNEL-positive staining cells were identified. Nevertheless, at 72 h after administration of SQNJP, significant increase of TUNEL-positive staining cells was noted compared with those of the model group and control group (Figure 4).

Figure 4.

Figure 4

Apoptosis of HSCs and expression of α-SMA protein in control group (A-C), model group (D-F), and SQNJP group (G-I). Apoptosis indicated by TUNEL assay (B, E, H). Expression of α- SMA protein indicated by immuno-fluorescent assay (A, D, G). Double staining of HSCs apoptosis and expression of α- SMA protein (C, F, I).

Discussion

Currently, HSCs-apoptosis targeting therapeutical strategies has been approved to be promising for hepatic fibrosis treatment. In this study, our results showed that a traditional Chinese medicine, SQNJP, could effectively reduce CCl4 induced hepatic fibrosis in rats. Our results indicated that hydroxyproline content and expression of α-SMA protein were significantly decreased after SQNJP administration. In addition, remarkable apoptosis of HSCs was noted in CCl4 induced hepatic fibrosis rats compared with the model group and control group. All these suggested that SQNJP could exert anti-fibrotic effects in hepatic fibrosis rats via inhibition of HSCs activation.

Hydroxyproline has been specifically detected in collagen, which plays a major role in hepatic fibrosis [13]. Generally, it has been considered as an effective method to evaluate the expression of collagen in vitro or in vivo [14]. To our best knowledge, elevation of liver hydroxyproline content was closely associated with hepatic fibrosis without inducing cell necrosis, and at the same time, the increase of liver collagenase activity was identified [15]. In our study, significant decrease of hydroxyproline content was noticed after administration of SQNJP compared with the model group.

To date, to remove the causative agent is still the only effective therapy to terminate or even reverse hepatic fibrosis [16,17]. Nevertheless, the cellular and molecular mechanisms underlying hepatic fibrosis have been clearly depicted. Attempts have been carried out for the termination of the proliferation of activated HSCs through cell apoptosis for hepatic fibrosis. Although many of these approaches are experimentally effective in animal models with hepatic fibrosis, its clinical efficacy and safety in humans are still not well defined. A number of drugs are available to reduce the accumulation of scar tissue in animal models with chronic liver injury, such as rennin-angiotensin system blockers and antioxidants, however, the lack of clinical trials is still a great obstacle for their popularity in clinical practices [17].

Recently, more attention has been paid to the traditional Chinese medicine due to its characteristics with few side effects. For instance, many studies have been carried out to investigate the anti-fibrotic effects of herbal medicine. In a recent study, Parajuli et al reported PF2401-SF, a standard fraction of Salvia miltiorrhiza, could induce apoptosis of activated HSCs in vitro and in vivo. Additionally, a recent review summarized that traditional Chinese medicine and its effective components showed anti-fibrosis effects through inhibition of cell proliferation, regulation of cytokines and interference of signal transduction [18]. Several clinical trails have been carried out in China mainland using herbal medicine for treatment of hepatic fibrosis patients, but the results are still controversial [19]. SQNJP, an ancient traditional Chinese medicine consisted of Panax quinquefolius, Radix notoginseng, and endothelium corneum gigeriae galli, has been extensively used in clinical practices in China mainland with satisfactory clinical efficiencies [8]. Nevertheless, no study has been performed to investigate its anti-fibrotic efficiency in experimental animal models. In this study, the animals treated with SQNJP showed decreased hydroxyproline content in hepatic tissues. Meanwhile, expression of α-SMA protein decreased after treating with SQNJP compared with the model group. All these indicated that SQNJP could inhibit the activation of HSCs. Simultaneously, remarkable cell apoptosis of HSCs was noticed at 72 h after administration of SQNJP compared with the model group, which demonstrated that it may be involved in the amelioration of hepatic fibrosis through targeting the cell apoptosis of HSCs.

In conclusion, SQNJP showed satisfactory anti-fibrosis efficiency in rats with hepatic fibrosis through inhibiting cellular activation and inducing cell apoptosis of HSCs. Further randomly controlled trials are needed to investigate its clinical efficacy for treatment of hepatic fibrosis.

Acknowledgements

This study was supported by the Zhejiang TCM Scientific Research Projects (No. 2011ZA112 and No. 2012ZB173).

Disclosure of conflict of interest

None.

References

  • 1.Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–456. doi: 10.1146/annurev-pathol-011110-130246. [DOI] [PubMed] [Google Scholar]
  • 2.Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172. doi: 10.1152/physrev.00013.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–1669. doi: 10.1053/j.gastro.2008.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wang X, Ikejima K, Kon K, Arai K, Aoyama T, Okumura K, Abe W, Sato N, Watanabe S. Ursolic acid ameliorates hepatic fibrosis in the rat by specific induction of apoptosis in hepatic stellate cells. J Hepatol. 2011;55:379–387. doi: 10.1016/j.jhep.2010.10.040. [DOI] [PubMed] [Google Scholar]
  • 5.Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J, Benyon RC, Iredale JP. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 2001;48:548–557. doi: 10.1136/gut.48.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Inao M, Mochida S, Matsui A, Eguchi Y, Yulutuz Y, Wang Y, Naiki K, Kakinuma T, Fujimori K, Nagoshi S, Fujiwara K. Japanese herbal medicine Inchin-ko-to as a therapeutic drug for liver fibrosis. J Hepatol. 2004;41:584–591. doi: 10.1016/j.jhep.2004.06.033. [DOI] [PubMed] [Google Scholar]
  • 7.Li C, Luo J, Li L, Cheng M, Huang N, Liu J, Waalkes MP. The collagenolytic effects of the traditional Chinese medicine preparation, Han-Dan-Gan-Le, contribute to reversal of chemical-induced liver fibrosis in rats. Life Sci. 2003;72:1563–1571. doi: 10.1016/s0024-3205(02)02448-7. [DOI] [PubMed] [Google Scholar]
  • 8.Liu P. Optimization of individual therapeutical strategy for hepatic fibrosis and cirrhosis. Chin J of Hepa. 2008;16:179–181. [Google Scholar]
  • 9.Xie H. Shen Qi Nei Jin San powder combined with lamivudine for the treatment of hepatic cirrhosis in patients with chronic hepatitis B. Chin J Inte Trad & West Med on Liver Dis. 2011;21:46–48. [Google Scholar]
  • 10.Deng YR, Ma HD, Tsuneyama K, Yang W, Wang YH, Lu FT, Liu CH, Liu P, He XS, Diehl AM, Gershwin ME, Lian ZX. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimmun. 2013;46:25–34. doi: 10.1016/j.jaut.2013.07.008. [DOI] [PubMed] [Google Scholar]
  • 11.Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem. 1981;112:70–75. doi: 10.1016/0003-2697(81)90261-x. [DOI] [PubMed] [Google Scholar]
  • 12.Cheng CC, Lin NN, Lee YF, Wu LY, Hsu HP, Lee WJ, Tung KC, Chiun YT. Effects of Shugan-Huayu powder, a traditional Chinese medicine, on hepatic fibrosis in rat model. Chin J Physiol. 2010;53:223–233. doi: 10.4077/cjp.2010.amk050. [DOI] [PubMed] [Google Scholar]
  • 13.Toyoki Y, Sasaki M, Narumi S, Yoshihara S, Morita T, Konn M. Semiquantitative evaluation of hepatic fibrosis by measuring tissue hydroxyproline. Hepatogastroenterology. 1998;45:2261–2264. [PubMed] [Google Scholar]
  • 14.Kim HK, Yang TH, Cho HY. Antifibrotic effects of green tea on in vitro and in vivo models of liver fibrosis. World J Gastroenterol. 2009;15:5200–5205. doi: 10.3748/wjg.15.5200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Watanabe A, Yamauchi Y, Kobayashi M, Nagashima H. Rapid elevation of liver hydroxyproline content following a single administration of various chemical carcinogens to rats. Res Exp Med (Berl) 1989;189:43–46. doi: 10.1007/BF01856028. [DOI] [PubMed] [Google Scholar]
  • 16.Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21:437–451. doi: 10.1055/s-2001-17558. [DOI] [PubMed] [Google Scholar]
  • 17.Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218. doi: 10.1172/JCI24282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sun SJ, Xiang Y, Huang SL. Progress in studies of mechanism of anti-fibrosis traditional Chinese drugs and effective components. Zhongguo Zhong Yao Za Zhi. 2008;33:2882–2886. [PubMed] [Google Scholar]
  • 19.Cheung F, Feng Y, Wang N, Yuen MF, Tong Y, Wong VT. Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. Chin Med. 2012;7:5. doi: 10.1186/1749-8546-7-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Clinical and Experimental Medicine are provided here courtesy of e-Century Publishing Corporation

RESOURCES